The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design
- 1 October 2005
- journal article
- research article
- Published by Elsevier BV in Journal of Cardiac Failure
- Vol. 11 (8), 576-585
- https://doi.org/10.1016/j.cardfail.2005.06.432
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Diastolic Heart Failure — Abnormalities in Active Relaxation and Passive Stiffness of the Left VentricleNew England Journal of Medicine, 2004
- Diastolic heart failure: the forgotten manifestation of hypertensive heart disease.Current Hypertension Reports, 2004
- The epidemiological enigma of heart failure with preserved systolic functionEuropean Journal of Heart Failure, 2004
- Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosisJournal of the American College of Cardiology, 2004
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialThe Lancet, 2003
- The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosisEuropean Heart Journal, 2003
- Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of CardiologyEuropean Journal of Heart Failure, 2002
- Heart Failure With a Normal Ejection FractionCirculation, 2001
- Importance of heart failure with preserved systolic function in patients ≥65 years of ageThe American Journal of Cardiology, 2001
- Congestive heart failure in subjects with normal versus reduced left ventricular ejection fractionJournal of the American College of Cardiology, 1999